<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01748396</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-FGF23</org_study_id>
    <nct_id>NCT01748396</nct_id>
  </id_info>
  <brief_title>Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol</brief_title>
  <official_title>Effect of Phosphate Binders on FGF-23 During Calcitriol Administration in CKD Stage 3 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic kidney disease (CKD) is an established risk factor for cardiovascular morbidity and
      mortality, as shown by common manifestations of left ventricular hypertrophy (LVH) and
      arterial calcifications in CKD patients. Fibroblast growth factor-23(FGF-23) is a recently
      identified phosphaturic hormone that has been reported to be associated with the development
      of secondary hyperparathyroidism, cardiovascular morbidity, mortality, CKD progression.

      While vitamin D is the mainstay therapy in CKD mineral bone disease (CKD-MBD), increased
      FGF-23 levels have been reported with vitamin D administration. The purpose of this study was
      to investigate the effect of calcium carbonate when used in conjunction with calcitriol on
      FGF-23.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent changes in FGF-23</measure>
    <time_frame>8 weeks after administration</time_frame>
    <description>Comparison of percent changes in FGF-23 from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent changes in Ca</measure>
    <time_frame>8 weeks after administration</time_frame>
    <description>Comparison of percent change in Ca from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent changes in P</measure>
    <time_frame>8 weeks after administration</time_frame>
    <description>Comparison of percent change in P from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent changes in iPTH</measure>
    <time_frame>8 weeks after administration</time_frame>
    <description>Comparison of percent change in intact parathyroid hormone from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent changes in 25(OH)D</measure>
    <time_frame>8 weeks after administration</time_frame>
    <description>Comparison of percent change in 25(OH)D from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent changes in 1,25(OH)2D</measure>
    <time_frame>8 weeks after administration</time_frame>
    <description>Comparison of percent change in 1,25(OH)2D from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Chronic Kidney Disease Stage 3</condition>
  <arm_group>
    <arm_group_label>Calcitriol + CaCO3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calcitriol 0.25mcg 1cap daily for 8 weeks, and Calcium Carbonate 500mg 1tab 3 times daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcitriol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcitriol 0.25mcg 1cap daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitriol</intervention_name>
    <arm_group_label>Calcitriol + CaCO3</arm_group_label>
    <arm_group_label>Calcitriol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Carbonate</intervention_name>
    <arm_group_label>Calcitriol + CaCO3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults of 18~70 years of age

          -  CKD stage 3 patients (GFR: 30-60ml/min/1.73m2)

          -  Patients who've given consent to the trial

        Exclusion Criteria:

          -  Known allergy to Vitamin D or calcium carbonate

          -  Administration of vitamin D analogue or phosphate binders 3 months prior to study
             entry

          -  History of hypercalcemia (corrected serum calcium &gt; 10.5 mg/dL) or hypophosphatemia
             (serum phosphate &lt; 2.5 mg/dL) 3 months prior to study entry

          -  Patients with bone pathologies or diseases requiring vitamin D therapy that is
             unrelated to CKD-MBD

          -  Administration of concurrent medication , diseases, or history of surgeries that may
             affect bone-mineral metabolism or alter bone status

          -  Patients diagnosed with rapidly progressive glomerulonephritis(RPGN) or those in need
             of renal replacement therapy

          -  Patients with obstructive bowel diseases, or severe gastrointestinal diseases

          -  Patients with less than 2 years of life expectancy(ex. Malignancy diseases)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yon Su Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jung Mi Oh, Pharm.D.</last_name>
    <role>Study Chair</role>
    <affiliation>College of Pharmacy, Seoul National University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2012</study_first_submitted>
  <study_first_submitted_qc>December 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2012</study_first_posted>
  <last_update_submitted>February 14, 2013</last_update_submitted>
  <last_update_submitted_qc>February 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Yon Su Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>FGF-23</keyword>
  <keyword>Calcitriol</keyword>
  <keyword>Calcium carbonate</keyword>
  <keyword>CKD Stage 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

